Oncology Stock Analysis

TOI -  USA Stock  

USD 6.03  0.56  8.50%

The big decline in price over the last few months for The Oncology Institute created some momentum for stockholders as it was traded today as low as 5.8 and as high as 6.4 per share. The company directors and management failed to add value to investors and positioning the company supply of money to exploit market volatility in December. However, diversifying your holdings with The Oncology Institute or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.77. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Oncology Institute partners.
Additionally, take a look at World Market Map.

Oncology Stock Analysis 

The Oncology Institute stock analysis report makes it easy to digest most publicly released information about Oncology Institute and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Oncology Stock analysis module also helps to analyze the Oncology Institute price relationship with some important fundamental indicators such as market cap and management efficiency.

Oncology Stock Analysis Notes

About 34.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 602.09. The Oncology Institute had not issued any dividends in recent years. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The company was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 605 people. To find out more about The Oncology Institute contact the company at 213 760 1328.

The Oncology Institute Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Oncology Institute's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding The Oncology Institute or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Oncology Institute generated a negative expected return over the last 90 days
Oncology Institute has high historical volatility and very poor performance
The company reported the last year's revenue of 199.66 M. Reported Net Loss for the year was (5.59 M) with profit before taxes, overhead, and interest of 36.88 M.
The Oncology Institute has about 11.53 M in cash with (10.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16.
Over 85.0% of the company shares are owned by institutional investors
Latest headline from www.marketscreener.com: Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session - Form 8-K - marketscreener.com

Oncology Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 463.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncology Institute's market, we take the total number of its shares issued and multiply it by Oncology Institute's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Oncology Profitablity

Oncology Institute's profitability indicators refer to fundamental financial ratios that showcase Oncology Institute's ability to generate income relative to its revenue or operating costs. If, let's say, Oncology Institute is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Oncology Institute's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Oncology Institute's profitability requires more research than a typical breakdown of Oncology Institute's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (2.8) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (5.01) %, which entails that for every $100 of revenue, it lost -0.05.

Management Efficiency

Oncology Institute management efficiency ratios could be used to measure how well the oncology institute manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of January, Oncology Institute holds the market risk adjusted performance of (0.19), and Coefficient Of Variation of (2,022). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncology Institute, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for The Oncology Institute, which can be compared to its competitors. Please check The Oncology Institute information ratio, as well as the relationship between the potential upside and kurtosis to decide if The Oncology Institute is priced some-what accurately, providing market reflects its current price of 6.03 per share. Given that Oncology Institute has jensen alpha of (0.30), we recommend you to check out The Oncology Institute's recent market performance to make sure the company can sustain itself at a future point.

The Oncology Institute Price Movement Analysis

The output start index for this execution was one with a total number of output elements of fifty-one. The Simple Moving Average indicator is calculated by adding the closing price of Oncology Institute for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out The Oncology Institute short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

The Oncology Institute Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncology Institute insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Oncology Institute Technical and Predictive Indicators

Oncology Institute Forecast Models

Oncology Institute time-series forecasting models is one of many Oncology Institute's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncology Institute's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Oncology Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncology Institute stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncology shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Oncology Institute. By using and applying Oncology Stock analysis, traders can create a robust methodology for identifying Oncology entry and exit points for their positions.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The company was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 605 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Oncology Institute to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamental Analysis Now


Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the The Oncology Institute information on this page should be used as a complementary analysis to other Oncology Institute's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Oncology Stock analysis

When running The Oncology Institute price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Oncology Institute's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of The Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine Oncology Institute value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.